GO:0016273 arginine N-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016273 (arginine N-methyltransferase activity) is a molecular function that transfers a methyl group from S-adenosyl-L-methionine to the amino group of an arginine residue.
• Protein arginine N-methyltransferases (PRMTs) are the principal enzymes carrying this activity and methylate histone and non-histone substrates.
• PRMT1 and PRMT2 cooperate in histone methylation, with PRMT2 playing a noncatalytic role in the histone methylation activity of PRMT1.
• PRMT4 (CARM1) contributes to glucose-induced skeletal muscle atrophy and to lymphopenia in experimental sepsis.
• PRMT9-mediated arginine methylation supports cancer stem cell maintenance and suppresses cGAS-mediated anticancer immunity.
• PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer, and PRMT inhibitors are under active patent development.
Description
Arginine N-methyltransferase activity (GO:0016273) is a molecular function that enables the transfer of a methyl group from S-adenosyl-L-methionine to an amino group of an arginine residue. This activity is central to the post-translational modification known as arginine methylation, which influences protein-protein interactions, chromatin structure, RNA processing, and signal transduction. Because arginine methylation is reversible and dynamically regulated, it has become a major focus in epigenetics, cancer biology, and immunology. Researchers studying this activity need reliable assays and models to determine how individual PRMTs contribute to normal physiology and disease. The sections below summarize the definition, mechanism, key genes, disease links, and experimental methods for GO:0016273, based on published literature.
arginine N-methyltransferase activity At A Glance
| GO ID | GO:0016273 |
|---|---|
| GO term | arginine N-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfer of a methyl group from S-adenosyl-L-methionine to an arginine residue |
| Enzyme family | Protein arginine N-methyltransferases (PRMTs) |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor |
| Substrates | Histone and non-histone proteins containing arginine residues |
| Related modifications | Monomethylation, asymmetric dimethylation, symmetric dimethylation |
What Is GO:0016273?
GO:0016273 describes the catalytic activity of enzymes that transfer a methyl group from S-adenosyl-L-methionine (SAM) to the amino group of an arginine residue in a protein substrate. This activity produces S-adenosyl-L-homocysteine and a methylarginine residue, most commonly asymmetric or symmetric dimethylarginine. The term is classified as a molecular_function in the Gene Ontology and is used to annotate protein arginine N-methyltransferases (PRMTs) and related enzymes.
Why Is arginine N-methyltransferase activity Important in Cell Biology?
Arginine N-methyltransferase activity is important because it controls a reversible post-translational modification that affects chromatin remodeling, transcription, RNA splicing, DNA repair, and signal transduction. Dysregulation of this activity has been linked to cancer, metabolic disorders, immune dysfunction, and neurological conditions. Because PRMTs are druggable enzymes, they are attractive targets for therapeutic development, and patents on PRMT inhibitors have grown steadily. Understanding GO:0016273 therefore has direct implications for both basic biology and translational medicine.
• Regulates histone methylation patterns and chromatin states.
• Controls non-histone protein functions such as STAT3 signaling in cancer.
• Modulates skeletal muscle atrophy under high glucose conditions.
• Contributes to lymphopenia during experimental sepsis.
• Supports cancer stem cell maintenance and immune evasion.
• Is a target for small-molecule PRMT inhibitors in drug discovery.
• Provides a mechanism for dynamic regulation of protein-protein interactions.
• Is measurable with quantitative enzymatic assays for screening.
• Links metabolism (SAM availability) to epigenetic regulation.
• Offers biomarkers and therapeutic hypotheses in oncology and immunology.
Molecular Mechanism of arginine N-methyltransferase activity
Substrate recognition and SAM binding
In simple terms: The enzyme first grabs its methyl donor and its target protein.
PRMT enzymes bind S-adenosyl-L-methionine (SAM) and a protein substrate containing a target arginine residue. Substrate recognition often depends on sequence motifs and adaptor proteins, as shown for PRMT1 and PRMT2 in histone methylation.
Methyl transfer and product formation
In simple terms: The enzyme hands a methyl group to the arginine.
The methyl group is transferred from SAM to the guanidino nitrogen of arginine, yielding S-adenosyl-L-homocysteine and methylarginine. Depending on the enzyme, the product can be monomethylarginine or dimethylarginine (asymmetric or symmetric).
Noncatalytic roles of PRMTs
In simple terms: Some PRMTs help other PRMTs work without doing the chemistry themselves.
PRMT2 plays a noncatalytic role in the histone methylation activity of PRMT1, indicating that PRMT complexes can have structural or regulatory subunits. This expands the functional repertoire beyond the catalytic transfer reaction alone.
Cofactors and regulation
In simple terms: The reaction depends on SAM and can be tuned by cellular signals.
SAM availability and the cellular methylation potential influence the rate of arginine methylation. PRMT activity can also be regulated by interacting proteins, post-translational modifications, and substrate availability.
Detection and quantification
In simple terms: Scientists use assays to measure how much methylation happens.
The filter binding and phosphor screening (FBAPS) assay allows determination of PRMT activity by measuring transfer of radiolabeled methyl groups. Such assays are used to screen inhibitors and to compare PRMT isoforms.
Key Genes Involved in GO:0016273 arginine N-methyltransferase activity
The following genes encode proteins that carry or regulate arginine N-methyltransferase activity (GO:0016273) and are supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRMT1 | Major asymmetric arginine methyltransferase; methylates histones and non-histone proteins | Core enzyme for GO:0016273; interacts with PRMT2 |
| PRMT2 | Noncatalytic regulator of PRMT1-mediated histone methylation | Modulates PRMT1 activity and substrate specificity |
| PRMT4 (CARM1) | Arginine methyltransferase involved in muscle and immune biology | Linked to glucose-induced muscle atrophy and sepsis lymphopenia |
| PRMT6 | Methylates STAT3 and other substrates | Regulates tumor metastasis in breast cancer |
| PRMT9 | Arginine methyltransferase affecting cancer stem cells | Suppresses cGAS-mediated anticancer immunity |
| PRMT5 | Symmetric arginine methyltransferase | Broad role in splicing and cancer; target of inhibitors |
| PRMT7 | Type III arginine methyltransferase | Studied for substrate specificity and development |
| PRMT3 | Arginine methyltransferase with zinc-finger domain | Model for substrate recognition |
| PRMT8 | Membrane-associated arginine methyltransferase | Tissue-specific functions in neurons |
| STAT3 | Transcription factor methylated by PRMT6 | Readout of PRMT6 activity in cancer |
| Histone H3 | Substrate of PRMT1/PRMT4 | Chromatin mark for epigenetic studies |
| Histone H4 | Substrate of PRMT1/PRMT5 | Arginine methylation mark in genome-wide profiling |
| S-adenosyl-L-methionine (SAM) | Methyl donor cofactor | Central metabolite for all PRMT reactions |
| S-adenosyl-L-homocysteine (SAH) | Reaction product and feedback inhibitor | Used in activity assays |
| PRMT inhibitors (chemical probes) | Small molecules targeting PRMTs | Patent landscape for drug discovery |
| cGAS | Immune sensor affected by PRMT9 loss | Anticancer immunity pathway |
| CARM1 (PRMT4) | Coactivator-associated arginine methyltransferase | Metabolic and immune disease models |
How Is arginine N-methyltransferase activity Regulated?
Arginine N-methyltransferase activity is regulated at multiple levels. Substrate availability and SAM/SAH balance directly affect catalytic rate. Protein-protein interactions, such as the noncatalytic role of PRMT2 in PRMT1-mediated histone methylation, modulate activity and targeting. In disease contexts, PRMT4 activation contributes to glucose-induced skeletal muscle atrophy, indicating metabolic regulation. PRMT9-mediated arginine methylation suppresses cGAS-mediated anticancer immunity, showing that this activity is integrated with immune signaling. PRMT6 methylation of STAT3 regulates tumor metastasis, linking this activity to oncogenic transcription. Finally, small-molecule PRMT inhibitors are being developed to pharmacologically control this activity.
arginine N-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRMT9 | Cancer stem cell maintenance and immune evasion | Knockout in cancer cell lines; cGAS reporter assays |
| PRMT6 | Breast cancer metastasis via STAT3 methylation | Point-mutation of STAT3 methylation site; xenograft models |
| PRMT4 (CARM1) | Glucose-induced skeletal muscle atrophy | Knockout or overexpression in myotubes; high-glucose treatment |
| PRMT4 (CARM1) | Sepsis-associated lymphopenia | Knockout mice in experimental sepsis models |
| PRMT1/PRMT2 | Histone methylation and chromatin regulation | Knockout and tagged knock-in in cell lines; ChIP-seq |
Cancer
PRMT9-mediated arginine methylation supports cancer stem cell maintenance and suppresses cGAS-mediated anticancer immunity, suggesting that inhibiting this activity could enhance antitumor immunity. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer, providing a mechanistic link between arginine methylation and metastatic progression. PRMT inhibitors are under active patent development for cancer therapy.
Metabolic and muscle disorders
PRMT4 activation contributes to glucose-induced skeletal muscle atrophy, indicating that arginine N-methyltransferase activity is involved in metabolic stress responses in muscle.
Immune dysfunction and sepsis
PRMT4 contributes to lymphopenia in experimental sepsis, linking arginine methylation to immune cell survival during systemic inflammation.
From arginine N-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PRMT1 reduce global arginine methylation? | PRMT1 knockout cell line |
| Does PRMT2 regulate PRMT1 activity noncatalytically? | PRMT2 knockout and rescue with catalytic-dead mutant |
| Does PRMT6 methylation of STAT3 promote metastasis? | STAT3 point-mutation knock-in in breast cancer cells |
| Does PRMT9 loss activate cGAS-mediated immunity? | PRMT9 knockout in cancer stem cells; cGAS reporter |
| Does PRMT4 activation drive muscle atrophy? | PRMT4 overexpression in skeletal muscle cells under high glucose |
| Can PRMT inhibitors block arginine methylation? | Enzymatic FBAPS assay with recombinant PRMTs |
How to Study the arginine N-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| FBAPS assay | Arginine N-methyltransferase activity via radiolabeled methyl transfer | PRMT isoform comparison and inhibitor screening |
| ChIP-seq | Genome-wide histone methylation marks | Chromatin profiling of PRMT substrates |
| Western blot with methyl-arginine antibodies | Global or site-specific arginine methylation | Validation of PRMT knockout or inhibition |
| Knockout/rescue | Catalytic vs noncatalytic contributions | Dissecting PRMT2-PRMT1 interaction |
| Cancer stem cell assays | Self-renewal and cGAS pathway activation | PRMT9 loss-of-function studies |
| Metastasis models | Tumor dissemination | PRMT6-STAT3 axis in breast cancer |
| Muscle atrophy assays | Myotube size and atrophy markers | PRMT4 activation under high glucose |
| Sepsis models | Lymphocyte survival | PRMT4 contribution to lymphopenia |
Enzymatic activity assays
The filter binding and phosphor screening (FBAPS) assay measures transfer of radiolabeled methyl groups from SAM to protein substrates, enabling quantification of arginine N-methyltransferase activity. This method is suitable for comparing PRMT isoforms and testing inhibitors.
Genome-wide histone methylation profiling
High-resolution profiling of histone methylations, such as ChIP-seq, maps arginine methylation marks across the genome and links PRMT activity to chromatin states.
Genetic perturbation and rescue
Knockout of PRMT genes followed by rescue with wild-type or catalytic-dead constructs can distinguish catalytic from noncatalytic functions, as shown for PRMT2 in PRMT1-mediated histone methylation.
Disease-relevant functional assays
Cell-based assays such as glucose-induced muscle atrophy models, sepsis lymphopenia models, and cancer stem cell assays can test the contribution of specific PRMTs to disease phenotypes.
How CRISPR Can Be Used to Study GO:0016273 arginine N-methyltransferase activity
Knockout
CRISPR knockout of PRMT genes such as PRMT1, PRMT2, PRMT4, PRMT6, and PRMT9 can reveal loss-of-function phenotypes in histone methylation, cancer stem cell maintenance, muscle atrophy, and immune responses.
Point Mutation
Point mutations can be introduced into catalytic residues of PRMTs or into methylation acceptor sites such as STAT3 arginines to test whether specific methylation events drive disease phenotypes.
Knock-in
Knock-in of tagged or mutant PRMT alleles allows tracking of protein localization and interaction partners while preserving endogenous regulation.
Overexpression
Overexpression of PRMT4 or other PRMTs can model gain-of-function states observed in metabolic stress or cancer, enabling testing of PRMT inhibitors.
How EDITGENE Supports arginine N-methyltransferase activity Research
Researchers studying arginine N-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as histone methylation, cancer stem cell maintenance, or muscle atrophy. CRISPR-based models provide a direct way to test causality by deleting, mutating, tagging, or overexpressing the gene of interest in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for arginine N-methyltransferase activity research.
Frequently Asked Questions About arginine N-methyltransferase activity
What is arginine N-methyltransferase activity?
It is a molecular function (GO:0016273) that transfers a methyl group from S-adenosyl-L-methionine to an arginine residue in a protein substrate.
What genes are involved in arginine N-methyltransferase activity?
Key genes include PRMT1, PRMT2, PRMT4 (CARM1), PRMT6, and PRMT9, among other PRMT family members.
What is the GO ID for arginine N-methyltransferase activity?
The GO ID is GO:0016273.
How is arginine N-methyltransferase activity measured?
It can be measured with the filter binding and phosphor screening (FBAPS) assay using radiolabeled SAM.
What diseases are linked to arginine N-methyltransferase activity?
It has been linked to cancer, skeletal muscle atrophy, and sepsis-associated lymphopenia.
What is the role of PRMT2 in arginine methylation?
PRMT2 plays a noncatalytic role in the histone methylation activity of PRMT1.
How does PRMT6 contribute to breast cancer?
PRMT6 methylates STAT3 and regulates tumor metastasis in breast cancer.
Can PRMT inhibitors target arginine N-methyltransferase activity?
Yes, small-molecule PRMT inhibitors are under active development and patent review.
What is the substrate of arginine N-methyltransferase?
The methyl donor is S-adenosyl-L-methionine, and the substrate is a protein containing a target arginine residue.
How can CRISPR help study arginine N-methyltransferase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of PRMT genes in disease-relevant cells.
Conclusion
Arginine N-methyltransferase activity (GO:0016273) is a fundamental molecular function that controls protein arginine methylation and influences chromatin, signaling, metabolism, and immunity. The PRMT family enzymes, including PRMT1, PRMT2, PRMT4, PRMT6, and PRMT9, are central to this activity and have been implicated in cancer, muscle atrophy, and sepsis. Continued research using enzymatic assays, genome-wide profiling, and CRISPR models will clarify how this activity can be targeted therapeutically.
References
- 1. Rowley MJ et al.. 2023. Protein arginine N-methyltransferase 2 plays a noncatalytic role in the histone methylation activity of PRMT1.. J Biol Chem 299(12):105360 PMID: 37863263
- 2. Rowley MJ et al.. 2022. Protein arginine N-methyltransferase activity determination with filter binding and phosphor screening (FBAPS) assay.. Anal Biochem 653:114778 PMID: 35709928
- 3. Barski A et al.. 2007. High-resolution profiling of histone methylations in the human genome.. Cell 129(4):823-37 PMID: 17512414
- 4. Kumar P et al.. 2025. Protein Arginine N-Methyltransferase 4 Activation Contributes to Glucose-Induced Skeletal Muscle Atrophy.. FASEB J 39(20):e71135 PMID: 41078314
- 5. Lai Y et al.. 2023. Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis.. Thorax 78(4):383-393 PMID: 35354645
- 6. Dong H et al.. 2024. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.. Nat Cancer 5(4):601-624 PMID: 38413714
- 7. Chen Q et al.. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer.. Cell Death Dis 14(10):655 PMID: 37813837
- 8. Dong J et al.. 2022. An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022).. Expert Opin Ther Pat 32(12):1185-1205 PMID: 36594709
